244 related articles for article (PubMed ID: 34767074)
1. Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Kazama K; Shiozawa M; Numata M; Sugano N; Sato S; Uchiyama M; Sato M; Aoyama T; Tamagawa H; Oshima T; Yukawa N; Rino Y
Int J Colorectal Dis; 2022 Feb; 37(2):337-348. PubMed ID: 34767074
[TBL] [Abstract][Full Text] [Related]
2. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A
Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
Shinozaki K; Yamada T; Nasu J; Matsumoto T; Yuasa Y; Shiraishi T; Nagano H; Moriyama I; Fujiwara T; Miguchi M; Yoshida R; Nozaka K; Tanioka H; Nagasaka T; Kurisu Y; Kobayashi M; Tsuchihashi K; Inukai M; Kikuchi T; Nishina T
Int J Clin Oncol; 2021 Feb; 26(2):399-408. PubMed ID: 33097971
[TBL] [Abstract][Full Text] [Related]
6. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
7. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
8. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Stein A; Atanackovic D; Hildebrandt B; Stübs P; Brugger W; Hapke G; Steffens CC; Illerhaus G; Bluemner E; Stöhlmacher J; Bokemeyer C
Br J Cancer; 2015 Sep; 113(6):872-7. PubMed ID: 26335608
[TBL] [Abstract][Full Text] [Related]
9. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
11. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E;
ESMO Open; 2020 Nov; 5(6):e000944. PubMed ID: 33148620
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
[TBL] [Abstract][Full Text] [Related]
13. A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.
Kadowaki S; Masuishi T; Ura T; Sugiyama K; Mitani S; Narita Y; Taniguchi H; Muro K
Int J Clin Oncol; 2021 Apr; 26(4):701-707. PubMed ID: 33386556
[TBL] [Abstract][Full Text] [Related]
14. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
Antoniotti C; Germani MM; Rossini D; Lonardi S; Pietrantonio F; Santini D; Marmorino F; Allegrini G; Daniel F; Raimondi A; Borelli B; Zaniboni A; Conca V; Abraham J; Spetzler D; Maiello E; Boccaccino A; Passardi A; Giordano M; Tamburini E; Korn MW; Masi G; Cremolini C
Eur J Cancer; 2022 May; 167():23-31. PubMed ID: 35366570
[TBL] [Abstract][Full Text] [Related]
15. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
17. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
18. FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Leal F; Ferreira FP; Sasse AD
Clin Colorectal Cancer; 2017 Dec; 16(4):405-409.e2. PubMed ID: 28433602
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
[TBL] [Abstract][Full Text] [Related]
20. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
